(-)-demecolcine increases expression ISO RGD:734299 6480464 Demecolcine results in increased expression of BCL2L11 mRNA CTD PMID:23649840 (S)-amphetamine multiple interactions ISO RGD:734299 6480464 [N-Methyl-3 more ... CTD PMID:23820845 (S)-amphetamine increases expression ISO RGD:734299 6480464 Dextroamphetamine results in increased expression of BCL2L11 mRNA, Dextroamphetamine results in increased expression of BCL2L11 protein CTD PMID:23820845 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane increases expression EXP 6480464 o more ... CTD PMID:22937105 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane decreases expression EXP 6480464 o, p'-DDT analog results in decreased expression of BCL2L11 mRNA CTD PMID:22937105 1,1-dichloroethene increases expression ISO RGD:734300 6480464 vinylidene chloride results in increased expression of BCL2L11 mRNA CTD PMID:26682919 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene increases expression EXP 6480464 Mitotane results in increased expression of BCL2L11 mRNA CTD PMID:23485034 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of BCL2L11 mRNA CTD PMID:30723492 17beta-estradiol affects expression ISO RGD:734299 6480464 Estradiol affects the expression of BCL2L11 mRNA CTD PMID:21826169 17beta-estradiol increases expression ISO RGD:734299 6480464 Estradiol results in increased expression of BCL2L11 mRNA CTD PMID:23373633 , PMID:24481588 1H-pyrazole increases expression ISO RGD:734300 6480464 pyrazole results in increased expression of BCL2L11 mRNA CTD PMID:17945193 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:734300 6480464 2 more ... CTD PMID:21851831 2,2',4,4'-Tetrabromodiphenyl ether affects expression ISO RGD:734299 6480464 2 more ... CTD PMID:27589474 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA CTD PMID:19520675 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:734300 6480464 Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA CTD PMID:15800033 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:734300 6480464 Tetrachlorodibenzodioxin affects the expression of BCL2L11 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:734300 6480464 2 more ... CTD PMID:21851831 , PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:734300 6480464 Tetrachlorodibenzodioxin results in decreased expression of BCL2L11 mRNA CTD PMID:19770486 2,4,6-trinitrobenzenesulfonic acid multiple interactions ISO RGD:734300 6480464 [Trinitrobenzenesulfonic Acid results in increased expression of MAPK9 protein] promotes the reaction [BCL2L11 protein binds to MAPK9 protein] more ... CTD PMID:22427801 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:734300 6480464 Trinitrobenzenesulfonic Acid results in increased expression of BCL2L11 protein CTD PMID:22427801 2-butoxyethanol increases expression ISO RGD:734300 6480464 n-butoxyethanol results in increased expression of BCL2L11 mRNA CTD PMID:19812364 2-methoxyethanol increases expression EXP 6480464 methyl cellosolve results in increased expression of BCL2L11 mRNA CTD PMID:19643169 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:23196670 3,4-methylenedioxymethamphetamine multiple interactions ISO RGD:734299 6480464 [N-Methyl-3 more ... CTD PMID:23820845 3,4-methylenedioxymethamphetamine increases expression ISO RGD:734299 6480464 N-Methyl-3 more ... CTD PMID:23820845 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:734299 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA CTD PMID:28628672 4-hydroxynon-2-enal increases expression ISO RGD:734300 6480464 4-hydroxy-2-nonenal results in increased expression of BCL2L11 mRNA CTD PMID:19191707 4-hydroxyphenyl retinamide increases expression ISO RGD:734300 6480464 Fenretinide results in increased expression of BCL2L11 mRNA CTD PMID:28973697 4-nonylphenol increases expression EXP 6480464 4-nonylphenol results in increased expression of BCL2L11 protein CTD PMID:26804764 4-vinylcyclohexene dioxide affects expression ISO RGD:734300 6480464 4-vinyl-1-cyclohexene dioxide affects the expression of BCL2L11 mRNA CTD PMID:20829426 5-fluorouracil multiple interactions ISO RGD:734299 6480464 Fluorouracil affects the reaction [rebamipide results in decreased expression of BCL2L11 protein], rebamipide inhibits the reaction [Fluorouracil results in increased expression of BCL2L11 protein] CTD PMID:29054700 5-fluorouracil increases expression ISO RGD:734299 6480464 Fluorouracil results in increased expression of BCL2L11 protein CTD PMID:29054700 7-ketocholesterol affects localization ISO RGD:734299 6480464 7-ketocholesterol affects the localization of BCL2L11 protein CTD PMID:15955068 8-(4-chlorophenylthio)-cAMP increases expression ISO RGD:734300 6480464 8-((4-chlorophenyl)thio)cyclic-3' more ... CTD PMID:14996839 8-(4-chlorophenylthio)-cAMP increases response to substance ISO RGD:734300 6480464 BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3', 5'-AMP CTD PMID:14996839 8-(4-chlorophenylthio)-cAMP increases response to substance ISO RGD:734299 6480464 BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3', 5'-AMP CTD PMID:14996839 8-(4-chlorophenylthio)-cAMP increases expression ISO RGD:734299 6480464 8-((4-chlorophenyl)thio)cyclic-3', 5'-AMP results in increased expression of BCL2L11 protein CTD PMID:14996839 8-bromo-3',5'-cyclic AMP multiple interactions ISO RGD:734299 6480464 [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein CTD PMID:16709600 9,10-anthraquinone increases expression ISO RGD:734299 6480464 9, 10-anthraquinone analog results in increased expression of BCL2L11 protein CTD PMID:26915975 acetylsalicylic acid increases expression ISO RGD:734299 6480464 Aspirin results in increased expression of BCL2L11 mRNA CTD PMID:19936928 actinomycin D multiple interactions ISO RGD:734300 6480464 Dactinomycin inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 mRNA] CTD PMID:16166651 aflatoxin B1 increases expression ISO RGD:734300 6480464 Aflatoxin B1 results in increased expression of BCL2L11 mRNA CTD PMID:19770486 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of BCL2L11 mRNA CTD PMID:25378103 aldehydo-D-glucose multiple interactions EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]], resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] CTD PMID:25471227 aldehydo-D-glucose increases expression EXP 6480464 Glucose results in increased expression of BCL2L11 protein CTD PMID:25471227 all-trans-retinoic acid decreases expression ISO RGD:734299 6480464 Tretinoin results in decreased expression of BCL2L11 protein CTD PMID:19176369 amiodarone increases expression ISO RGD:734299 6480464 Amiodarone results in increased expression of BCL2L11 mRNA CTD PMID:19774075 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of BCL2L11 mRNA CTD PMID:16483693 anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions ISO RGD:734300 6480464 pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] CTD PMID:16166651 anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions ISO RGD:734299 6480464 pyrazolanthrone inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein] more ... CTD PMID:17317842 more ... antirheumatic drug decreases expression ISO RGD:734299 6480464 Antirheumatic Agents results in decreased expression of BCL2L11 mRNA CTD PMID:24449571 Aroclor 1254 increases expression ISO RGD:734300 6480464 Chlorodiphenyl (54% Chlorine) results in increased expression of BCL2L11 mRNA CTD PMID:25270620 asbestos decreases expression ISO RGD:734299 6480464 Asbestos results in decreased expression of BCL2L11 CTD PMID:27042963 Azaspiracid decreases expression ISO RGD:734299 6480464 azaspiracid results in decreased expression of BCL2L11 mRNA CTD PMID:28939011 belinostat increases expression ISO RGD:734299 6480464 belinostat results in increased expression of BCL2L11 protein CTD PMID:18223231 benzo[a]pyrene increases expression ISO RGD:734299 6480464 Benzo(a)pyrene results in increased expression of BCL2L11 mRNA CTD PMID:15735009 benzo[a]pyrene increases methylation ISO RGD:734300 6480464 Benzo(a)pyrene results in increased methylation of BCL2L11 gene CTD PMID:28476633 benzo[a]pyrene decreases expression ISO RGD:734299 6480464 Benzo(a)pyrene results in decreased expression of BCL2L11 mRNA CTD PMID:26238291 benzo[a]pyrene increases expression ISO RGD:734300 6480464 Benzo(a)pyrene results in increased expression of BCL2L11 mRNA CTD PMID:19770486 , PMID:21715664 benzo[a]pyrene decreases expression ISO RGD:734300 6480464 Benzo(a)pyrene results in decreased expression of BCL2L11 mRNA CTD PMID:20713471 benzo[b]fluoranthene increases expression ISO RGD:734300 6480464 benzo(b)fluoranthene results in increased expression of BCL2L11 protein CTD PMID:21392559 berberine multiple interactions ISO RGD:734299 6480464 [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA CTD PMID:26712469 berberine increases expression ISO RGD:734299 6480464 Berberine results in increased expression of BCL2L11 mRNA CTD PMID:26712469 bis(2-chloroethyl) sulfide increases expression ISO RGD:734300 6480464 Mustard Gas results in increased expression of BCL2L11 mRNA CTD PMID:18955075 bis(2-ethylhexyl) phthalate increases expression EXP 6480464 Diethylhexyl Phthalate results in increased expression of BCL2L11 mRNA CTD PMID:22610992 bisphenol A affects expression ISO RGD:734299 6480464 bisphenol A affects the expression of BCL2L11 mRNA CTD PMID:21826169 bisphenol A multiple interactions ISO RGD:734299 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA CTD PMID:28628672 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of BCL2L11 gene CTD PMID:28505145 bisphenol A increases methylation ISO RGD:734300 6480464 bisphenol A results in increased methylation of BCL2L11 promoter CTD PMID:27312807 bisphenol A increases expression ISO RGD:734300 6480464 bisphenol A results in increased expression of BCL2L11 protein CTD PMID:24909818 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of BCL2L11 mRNA CTD PMID:25181051 bisphenol A increases methylation ISO RGD:734299 6480464 bisphenol A results in increased methylation of BCL2L11 gene CTD PMID:22576693 bisphenol A decreases expression ISO RGD:734299 6480464 bisphenol A results in decreased expression of BCL2L11 mRNA CTD PMID:22576693 bortezomib multiple interactions ISO RGD:734299 6480464 [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein, Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] CTD PMID:15173094 bortezomib increases expression ISO RGD:734299 6480464 Bortezomib results in increased expression of BCL2L11 protein CTD PMID:16024631 more ... bortezomib increases activity ISO RGD:734299 6480464 Bortezomib results in increased activity of BCL2L11 protein CTD PMID:16446371 bortezomib increases response to substance ISO RGD:734299 6480464 BCL2L11 results in increased susceptibility to Bortezomib CTD PMID:18566236 Brevetoxin B increases expression ISO RGD:734299 6480464 brevetoxin 2 results in increased expression of BCL2L11 mRNA CTD PMID:20498034 cadmium dichloride increases expression ISO RGD:734299 6480464 Cadmium Chloride results in increased expression of BCL2L11 CTD PMID:21787858 cadmium dichloride increases expression EXP 6480464 Cadmium Chloride results in increased expression of BCL2L11 protein CTD PMID:28457857 calcitriol decreases expression ISO RGD:734299 6480464 Calcitriol results in decreased expression of BCL2L11 mRNA CTD PMID:12071473 carbamazepine affects expression ISO RGD:734299 6480464 Carbamazepine affects the expression of BCL2L11 mRNA CTD PMID:24752500 carbaryl decreases expression ISO RGD:734299 6480464 Carbaryl results in decreased expression of BCL2L11 mRNA CTD PMID:27829164 carbon nanotube increases expression ISO RGD:734300 6480464 Nanotubes, Carbon analog results in increased expression of BCL2L11 mRNA CTD PMID:25554681 chlorpyrifos increases expression ISO RGD:734300 6480464 Chlorpyrifos results in increased expression of BCL2L11 mRNA CTD PMID:27737797 chromium(6+) increases expression ISO RGD:734299 6480464 chromium hexavalent ion results in increased expression of BCL2L11 mRNA CTD PMID:17382205 chromium(6+) affects expression ISO RGD:734300 6480464 chromium hexavalent ion affects the expression of BCL2L11 mRNA CTD PMID:28472532 cisplatin multiple interactions ISO RGD:734299 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of BCL2L11 mRNA more ... CTD PMID:21092744 , PMID:27392435 cisplatin increases expression ISO RGD:734299 6480464 Cisplatin results in increased expression of BCL2L11 mRNA CTD PMID:21092744 , PMID:27392435 clofibrate multiple interactions ISO RGD:734300 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA] CTD PMID:17585979 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of BCL2L11 mRNA CTD PMID:24386269 cocaine increases expression EXP 6480464 Cocaine results in increased expression of BCL2L11 mRNA CTD PMID:16076954 copper atom multiple interactions EXP 6480464 [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein, [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein CTD PMID:22276220 copper(0) multiple interactions EXP 6480464 [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein, [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein CTD PMID:22276220 copper(2+) multiple interactions EXP 6480464 [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein, [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein CTD PMID:22276220 crizotinib increases expression ISO RGD:734299 6480464 crizotinib results in increased expression of BCL2L11 protein CTD PMID:22729845 crizotinib multiple interactions ISO RGD:734299 6480464 BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein], MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein] CTD PMID:22729845 crizotinib affects response to substance ISO RGD:734299 6480464 BCL2L11 protein affects the susceptibility to crizotinib CTD PMID:22729845 crocidolite asbestos decreases expression ISO RGD:734299 6480464 Asbestos, Crocidolite results in decreased expression of BCL2L11 mRNA CTD PMID:18687144 curcumin increases expression ISO RGD:734299 6480464 Curcumin results in increased expression of BCL2L11 mRNA CTD PMID:17332930 curcumin multiple interactions ISO RGD:734299 6480464 [arsenic trioxide co-treated with Curcumin] results in increased expression of BCL2L11 protein CTD PMID:27430728 D-glucose multiple interactions EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]], resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] CTD PMID:25471227 D-glucose increases expression EXP 6480464 Glucose results in increased expression of BCL2L11 protein CTD PMID:25471227 dactolisib affects expression ISO RGD:734299 6480464 dactolisib affects the expression of BCL2L11 protein CTD PMID:25640480 DDE affects expression EXP 6480464 Dichlorodiphenyl Dichloroethylene affects the expression of BCL2L11 mRNA CTD PMID:24576310 dexamethasone increases response to substance ISO RGD:734299 6480464 BCL2L11 protein results in increased susceptibility to Dexamethasone CTD PMID:14996839 dexamethasone increases response to substance ISO RGD:734300 6480464 BCL2L11 protein results in increased susceptibility to Dexamethasone CTD PMID:14996839 dexamethasone increases expression ISO RGD:734300 6480464 Dexamethasone results in increased expression of BCL2L11 mRNA alternative form, Dexamethasone results in increased expression of BCL2L11 protein CTD PMID:14996839 , PMID:17953376 dexamethasone multiple interactions ISO RGD:734299 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA more ... CTD PMID:18515658 more ... dexamethasone increases phosphorylation ISO RGD:734299 6480464 Dexamethasone results in increased phosphorylation of BCL2L11 protein CTD PMID:20067466 dexamethasone increases expression ISO RGD:734299 6480464 Dexamethasone results in increased expression of BCL2L11 mRNA CTD PMID:12782123 Di-n-octyl phthalate decreases expression ISO RGD:734300 6480464 di-n-octyl phthalate results in decreased expression of BCL2L11 protein CTD PMID:29128616 dibenzo[a,l]pyrene increases methylation ISO RGD:734300 6480464 dibenzo(a, l)pyrene results in increased methylation of BCL2L11 gene CTD PMID:28476633 dibutyl phthalate decreases expression ISO RGD:734300 6480464 Dibutyl Phthalate results in decreased expression of BCL2L11 mRNA CTD PMID:17361019 , PMID:21266533 diclofenac affects expression ISO RGD:734299 6480464 Diclofenac affects the expression of BCL2L11 mRNA CTD PMID:24752500 dicrotophos increases expression ISO RGD:734299 6480464 dicrotophos results in increased expression of BCL2L11 mRNA CTD PMID:28302478 dieldrin affects expression EXP 6480464 Dieldrin affects the expression of BCL2L11 mRNA CTD PMID:22546817 diepoxybutane increases expression ISO RGD:734299 6480464 diepoxybutane results in increased expression of BCL2L11 mRNA CTD PMID:29792945 Dinophysistoxin 1 increases expression ISO RGD:734299 6480464 dinophysistoxin 1 results in increased expression of BCL2L11 mRNA CTD PMID:28939011 dioxygen multiple interactions ISO RGD:734299 6480464 [Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein more ... CTD PMID:25472572 diquat increases expression ISO RGD:734300 6480464 Diquat results in increased expression of BCL2L11 mRNA CTD PMID:26785375 , PMID:27057282 diquat multiple interactions ISO RGD:734300 6480464 procyanidin B2 inhibits the reaction [Diquat results in increased expression of BCL2L11 mRNA] CTD PMID:27057282 dorsomorphin multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin multiple interactions ISO RGD:734299 6480464 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein more ... CTD PMID:17339365 , PMID:20856197 doxorubicin increases expression ISO RGD:734299 6480464 Doxorubicin results in increased expression of BCL2L11 protein CTD PMID:25339540 doxorubicin increases expression EXP 6480464 Doxorubicin results in increased expression of BCL2L11 protein CTD PMID:26318906 doxorubicin decreases expression ISO RGD:734299 6480464 Doxorubicin results in decreased expression of BCL2L11 protein CTD PMID:17339365 efavirenz increases expression ISO RGD:734299 6480464 efavirenz metabolite results in increased expression of BCL2L11 mRNA more ... CTD PMID:21958719 efavirenz increases response to substance ISO RGD:734299 6480464 BCL2L11 protein results in increased susceptibility to efavirenz metabolite CTD PMID:21958719 elemental selenium multiple interactions ISO RGD:734299 6480464 BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium] more ... CTD PMID:17339365 elemental selenium increases expression ISO RGD:734299 6480464 Selenium results in increased expression of BCL2L11 protein CTD PMID:17339365 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of BCL2L11 mRNA CTD PMID:29391264 enniatin decreases expression EXP 6480464 enniatins results in decreased expression of BCL2L11 mRNA CTD PMID:27163883 entinostat decreases expression ISO RGD:734299 6480464 entinostat results in decreased expression of BCL2L11 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA CTD PMID:27188386 epichlorohydrin decreases expression ISO RGD:734299 6480464 Epichlorohydrin results in decreased expression of BCL2L11 mRNA CTD PMID:29792945 erlotinib hydrochloride increases expression ISO RGD:734299 6480464 Erlotinib Hydrochloride results in increased expression of BCL2L11 protein CTD PMID:30171258 erlotinib hydrochloride multiple interactions ISO RGD:734299 6480464 Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] CTD PMID:30171258 ethanol increases expression ISO RGD:734300 6480464 Ethanol results in increased expression of BCL2L11 mRNA CTD PMID:24095927 ethanol multiple interactions ISO RGD:734299 6480464 [Ethanol co-treated with FOXO3 protein] results in increased expression of BCL2L11 mRNA more ... CTD PMID:26470730 ethyl methanesulfonate increases expression ISO RGD:734299 6480464 Ethyl Methanesulfonate results in increased expression of BCL2L11 mRNA CTD PMID:23649840 ferric oxide increases expression ISO RGD:734300 6480464 ferric oxide analog results in increased expression of BCL2L11 mRNA, ferric oxide analog results in increased expression of BCL2L11 protein CTD PMID:24525745 , PMID:25086211 flutamide increases expression EXP 6480464 Flutamide results in increased expression of BCL2L11 mRNA, Flutamide results in increased expression of BCL2L11 protein CTD PMID:20850791 , PMID:24793618 flutamide increases expression ISO RGD:734300 6480464 Flutamide results in increased expression of BCL2L11 protein CTD PMID:16301331 flutamide multiple interactions ISO RGD:734300 6480464 CBL protein affects the reaction [Flutamide results in increased expression of BCL2L11 protein] CTD PMID:16301331 fluvastatin multiple interactions ISO RGD:734299 6480464 [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA CTD PMID:16996129 folic acid affects expression ISO RGD:734299 6480464 Folic Acid affects the expression of BCL2L11 mRNA CTD PMID:16361273 formaldehyde increases expression ISO RGD:734299 6480464 Formaldehyde results in increased expression of BCL2L11 mRNA CTD PMID:23649840 furan increases expression EXP 6480464 furan results in increased expression of BCL2L11 mRNA CTD PMID:20562052 more ... furosemide affects expression EXP 6480464 Furosemide affects the expression of BCL2L11 mRNA CTD PMID:17497460 gallic acid decreases expression ISO RGD:734300 6480464 Gallic Acid results in decreased expression of BCL2L11 mRNA CTD PMID:29205955 gefitinib increases response to substance ISO RGD:734299 6480464 BCL2L11 protein results in increased susceptibility to gefitinib CTD PMID:20237869 gemcitabine increases expression ISO RGD:734299 6480464 gemcitabine results in increased expression of BCL2L11 mRNA CTD PMID:17039268 glucose multiple interactions EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]], resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] CTD PMID:25471227 glucose increases expression EXP 6480464 Glucose results in increased expression of BCL2L11 protein CTD PMID:25471227 gossypol increases expression ISO RGD:734299 6480464 Gossypol results in increased expression of BCL2L11 protein CTD PMID:18840529 harmine multiple interactions ISO RGD:734299 6480464 Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] CTD PMID:30171258 hydrogen peroxide increases expression ISO RGD:734300 6480464 Hydrogen Peroxide results in increased expression of BCL2L11 mRNA CTD PMID:27057282 hydrogen peroxide multiple interactions ISO RGD:734300 6480464 procyanidin B2 inhibits the reaction [Hydrogen Peroxide results in increased expression of BCL2L11 mRNA] CTD PMID:27057282 ibrutinib multiple interactions ISO RGD:734299 6480464 PCI 32765 promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:26254443 icariin affects expression EXP 6480464 icariin affects the expression of BCL2L11 protein CTD PMID:25472572 icariin multiple interactions ISO RGD:734299 6480464 icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] CTD PMID:25472572 indometacin multiple interactions ISO RGD:734299 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA CTD PMID:28628672 isoflurane decreases expression EXP 6480464 Isoflurane results in decreased expression of BCL2L11 mRNA CTD PMID:16978161 isoprenaline increases expression ISO RGD:734300 6480464 Isoproterenol results in increased expression of BCL2L11 protein CTD PMID:14996839 isoprenaline increases expression EXP 6480464 Isoproterenol results in increased expression of BCL2L11 mRNA CTD PMID:24286936 isoprenaline increases expression ISO RGD:734299 6480464 Isoproterenol results in increased expression of BCL2L11 mRNA CTD PMID:24286936 ketoconazole increases expression ISO RGD:734300 6480464 Ketoconazole results in increased expression of BCL2L11 mRNA CTD PMID:25808816 lead diacetate increases expression ISO RGD:734300 6480464 lead acetate results in increased expression of BCL2L11 mRNA CTD PMID:21829687 lovastatin multiple interactions ISO RGD:734299 6480464 pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] CTD PMID:18766339 lovastatin increases expression ISO RGD:734299 6480464 Lovastatin results in increased expression of BCL2L11 protein CTD PMID:18766339 LY294002 multiple interactions EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]] CTD PMID:25471227 LY294002 increases expression ISO RGD:734299 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form CTD PMID:21179458 LY294002 multiple interactions ISO RGD:734299 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein] more ... CTD PMID:20856197 more ... maneb increases expression ISO RGD:734299 6480464 Maneb results in increased expression of BCL2L11 protein CTD PMID:18266926 maneb multiple interactions ISO RGD:734299 6480464 [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein CTD PMID:18266926 manganese(II) chloride increases expression EXP 6480464 manganese chloride results in increased expression of BCL2L11 protein CTD PMID:25732873 manganese(II) chloride decreases expression EXP 6480464 manganese chloride results in decreased expression of BCL2L11 mRNA CTD PMID:28801915 Matrine multiple interactions ISO RGD:734299 6480464 arsenic trioxide promotes the reaction [matrine results in increased expression of BCL2L11 protein], matrine promotes the reaction [arsenic trioxide results in increased expression of BCL2L11 protein] CTD PMID:23700110 Matrine increases expression ISO RGD:734299 6480464 matrine results in increased expression of BCL2L11 protein CTD PMID:23700110 medroxyprogesterone acetate multiple interactions ISO RGD:734299 6480464 [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein CTD PMID:16709600 mercury atom decreases expression ISO RGD:734299 6480464 Mercury results in decreased expression of BCL2L11 mRNA CTD PMID:19937285 mercury dibromide decreases expression ISO RGD:734299 6480464 mercuric bromide results in decreased expression of BCL2L11 mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA CTD PMID:27188386 mercury(0) decreases expression ISO RGD:734299 6480464 Mercury results in decreased expression of BCL2L11 mRNA CTD PMID:19937285 mercury(2+) decreases expression ISO RGD:734299 6480464 Mercury results in decreased expression of BCL2L11 mRNA CTD PMID:19937285 methamphetamine increases expression ISO RGD:734299 6480464 Methamphetamine results in increased expression of BCL2L11 protein CTD PMID:23820845 methamphetamine multiple interactions ISO RGD:734299 6480464 [N-Methyl-3 more ... CTD PMID:23820845 methyl methanesulfonate increases expression ISO RGD:734299 6480464 Methyl Methanesulfonate results in increased expression of BCL2L11 mRNA CTD PMID:23649840 methylmercury chloride increases expression ISO RGD:734299 6480464 methylmercuric chloride results in increased expression of BCL2L11 mRNA CTD PMID:28001369 methylparaben increases expression ISO RGD:734299 6480464 methylparaben results in increased expression of BCL2L11 mRNA CTD PMID:24481588 methylseleninic acid multiple interactions ISO RGD:734299 6480464 BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with methylselenic acid] more ... CTD PMID:17339365 , PMID:18790785 methylseleninic acid increases expression ISO RGD:734299 6480464 methylselenic acid results in increased expression of BCL2L11 mRNA, methylselenic acid results in increased expression of BCL2L11 protein CTD PMID:17339365 , PMID:28161410 methylseleninic acid increases cleavage ISO RGD:734299 6480464 methylselenic acid results in increased cleavage of BCL2L11 protein CTD PMID:18790785 microcystin-LR increases expression ISO RGD:734300 6480464 cyanoginosin LR results in increased expression of BCL2L11 mRNA CTD PMID:17654400 monodansylcadaverine increases expression ISO RGD:734299 6480464 monodansylcadaverine results in increased expression of BCL2L11 protein CTD PMID:16170020 morphine increases expression ISO RGD:734299 6480464 Morphine results in increased expression of BCL2L11 protein CTD PMID:19292871 N-acetyl-L-cysteine multiple interactions ISO RGD:734299 6480464 Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] CTD PMID:15173094 N-methyl-4-phenylpyridinium increases expression ISO RGD:734299 6480464 1-Methyl-4-phenylpyridinium results in increased expression of BCL2L11 mRNA CTD PMID:18266926 N-methyl-4-phenylpyridinium decreases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2L11 mRNA CTD PMID:28801915 N-methyl-4-phenylpyridinium multiple interactions EXP 6480464 MIR181C mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BCL2L11 mRNA], MIR181C mRNA inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BCL2L11 protein] CTD PMID:28770951 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of BCL2L11 mRNA, 1-Methyl-4-phenylpyridinium results in increased expression of BCL2L11 protein CTD PMID:28770951 N-methyl-N'-nitro-N-nitrosoguanidine multiple interactions EXP 6480464 [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein, S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] CTD PMID:16030430 N-nitrosodiethylamine increases expression ISO RGD:734300 6480464 Diethylnitrosamine results in increased expression of BCL2L11 mRNA CTD PMID:24535843 nickel atom multiple interactions ISO RGD:734299 6480464 trichostatin A inhibits the reaction [Nickel affects the expression of BCL2L11 mRNA] CTD PMID:14575637 nickel atom affects expression ISO RGD:734299 6480464 Nickel affects the expression of BCL2L11 mRNA CTD PMID:14575637 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of BCL2L11 mRNA CTD PMID:22110744 nickel sulfate increases expression ISO RGD:734299 6480464 nickel sulfate results in increased expression of BCL2L11 mRNA CTD PMID:17382205 nicotinamide multiple interactions ISO RGD:734299 6480464 [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA, Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] CTD PMID:25472572 , PMID:26712469 nicotinamide increases expression ISO RGD:734299 6480464 Niacinamide results in increased expression of BCL2L11 mRNA CTD PMID:26712469 nimustine increases expression ISO RGD:734299 6480464 Nimustine results in increased expression of BCL2L11 mRNA, Nimustine results in increased expression of BCL2L11 protein CTD PMID:26418950 nimustine multiple interactions ISO RGD:734299 6480464 BCL2L11 mutant form inhibits the reaction [Nimustine results in increased cleavage of CASP9 protein], pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of BCL2L11 mRNA] CTD PMID:26418950 ochratoxin A decreases expression ISO RGD:734299 6480464 ochratoxin A results in decreased expression of BCL2L11 mRNA CTD PMID:30559759 , PMID:30763683 okadaic acid increases expression ISO RGD:734299 6480464 Okadaic Acid results in increased expression of BCL2L11 mRNA CTD PMID:28939011 osthole increases expression ISO RGD:734299 6480464 osthol results in increased expression of BCL2L11 protein alternative form CTD PMID:29319219 p-chloromercuribenzoic acid decreases expression ISO RGD:734299 6480464 p-Chloromercuribenzoic Acid results in decreased expression of BCL2L11 mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA CTD PMID:27188386 paclitaxel affects response to substance ISO RGD:734300 6480464 BCL2L11 protein affects the susceptibility to Paclitaxel CTD PMID:17652622 panobinostat decreases expression ISO RGD:734299 6480464 panobinostat results in decreased expression of BCL2L11 mRNA CTD PMID:26272509 panobinostat multiple interactions ISO RGD:734299 6480464 (+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein] more ... CTD PMID:24435446 , PMID:27188386 panobinostat increases expression ISO RGD:734299 6480464 panobinostat results in increased expression of BCL2L11 protein CTD PMID:24435446 paracetamol multiple interactions ISO RGD:734300 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA] CTD PMID:17585979 paracetamol decreases expression ISO RGD:734299 6480464 Acetaminophen results in decreased expression of BCL2L11 mRNA CTD PMID:26690555 paracetamol increases expression ISO RGD:734299 6480464 Acetaminophen results in increased expression of BCL2L11 mRNA CTD PMID:21420995 , PMID:25704631 paracetamol affects expression ISO RGD:734300 6480464 Acetaminophen affects the expression of BCL2L11 mRNA CTD PMID:17562736 paraquat decreases expression ISO RGD:734299 6480464 Paraquat results in decreased expression of BCL2L11 mRNA CTD PMID:18836921 paraquat multiple interactions ISO RGD:734299 6480464 [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein CTD PMID:18266926 paraquat increases expression ISO RGD:734299 6480464 Paraquat results in increased expression of BCL2L11 protein CTD PMID:18266926 paraquat multiple interactions ISO RGD:734300 6480464 FOXO3 mutant form inhibits the reaction [Paraquat results in increased expression of BCL2L11 mRNA] CTD PMID:23620592 paraquat increases expression ISO RGD:734300 6480464 Paraquat results in increased expression of BCL2L11 mRNA CTD PMID:23620592 patulin increases expression ISO RGD:734299 6480464 Patulin results in increased expression of BCL2L11 mRNA CTD PMID:21844328 phenobarbital decreases expression ISO RGD:734300 6480464 Phenobarbital results in decreased expression of BCL2L11 mRNA CTD PMID:19270015 phenobarbital affects expression ISO RGD:734300 6480464 Phenobarbital affects the expression of BCL2L11 mRNA CTD PMID:23091169 phenobarbital increases expression ISO RGD:734300 6480464 Phenobarbital results in increased expression of BCL2L11 mRNA CTD PMID:25270620 phenylmercury acetate decreases expression ISO RGD:734299 6480464 Phenylmercuric Acetate results in decreased expression of BCL2L11 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA CTD PMID:27188386 pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of BCL2L11 mRNA CTD PMID:12832660 ponatinib multiple interactions ISO RGD:734299 6480464 (+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of BCL2L11 protein], ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:25053825 ponatinib increases expression ISO RGD:734299 6480464 ponatinib results in increased expression of BCL2L11 protein CTD PMID:25053825 potassium chromate increases expression ISO RGD:734299 6480464 potassium chromate(VI) results in increased expression of BCL2L11 mRNA CTD PMID:17382205 proanthocyanidin decreases expression ISO RGD:734300 6480464 Proanthocyanidins results in decreased expression of BCL2L11 mRNA CTD PMID:29205955 prochloraz increases expression EXP 6480464 prochloraz results in increased expression of BCL2L11 mRNA CTD PMID:29038839 procyanidin B2 multiple interactions ISO RGD:734300 6480464 procyanidin B2 inhibits the reaction [Diquat results in increased expression of BCL2L11 mRNA], procyanidin B2 inhibits the reaction [Hydrogen Peroxide results in increased expression of BCL2L11 mRNA] CTD PMID:27057282 propylparaben increases expression ISO RGD:734299 6480464 propylparaben results in increased expression of BCL2L11 mRNA CTD PMID:24481588 protein kinase inhibitor multiple interactions ISO RGD:734299 6480464 Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of BCL2L11 mRNA] CTD PMID:28003376 quercetin increases expression ISO RGD:734299 6480464 Quercetin results in increased expression of BCL2L11 mRNA, Quercetin results in increased expression of BCL2L11 protein CTD PMID:25339540 , PMID:30152185 quercetin decreases expression ISO RGD:734299 6480464 Quercetin results in decreased expression of BCL2L11 protein CTD PMID:20438634 quizartinib multiple interactions ISO RGD:734299 6480464 (+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of BCL2L11 protein], quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:25053825 quizartinib increases expression ISO RGD:734299 6480464 quizartinib results in increased expression of BCL2L11 protein CTD PMID:25053825 raloxifene increases expression ISO RGD:734299 6480464 Raloxifene Hydrochloride results in increased expression of BCL2L11 mRNA CTD PMID:19429434 reactive oxygen species multiple interactions ISO RGD:734299 6480464 [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in decreased expression of BCL2L11 protein CTD PMID:27634759 Rebamipide decreases expression ISO RGD:734299 6480464 rebamipide results in decreased expression of BCL2L11 protein CTD PMID:29054700 Rebamipide multiple interactions ISO RGD:734299 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein] more ... CTD PMID:29054700 resveratrol multiple interactions ISO RGD:734299 6480464 BCL2L11 protein promotes the reaction [resveratrol results in increased activity of BAK1 protein] more ... CTD PMID:21179458 more ... resveratrol multiple interactions EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]], resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] CTD PMID:25471227 resveratrol increases expression ISO RGD:734300 6480464 resveratrol results in increased expression of BCL2L11 protein CTD PMID:20026400 , PMID:21980390 resveratrol increases expression ISO RGD:734299 6480464 resveratrol results in increased expression of BCL2L11 protein, resveratrol results in increased expression of BCL2L11 protein alternative form CTD PMID:17636462 more ... resveratrol increases response to substance ISO RGD:734299 6480464 BCL2L11 protein results in increased susceptibility to resveratrol CTD PMID:22245142 romidepsin multiple interactions ISO RGD:734299 6480464 [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein, Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] CTD PMID:15173094 romidepsin increases expression ISO RGD:734299 6480464 romidepsin results in increased expression of BCL2L11 protein CTD PMID:15069698 , PMID:18223231 S-allylcysteine multiple interactions EXP 6480464 S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] CTD PMID:16030430 SB 203580 multiple interactions EXP 6480464 SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of BCL2L11 protein] CTD PMID:16818494 SB 431542 multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 Se-methyl-L-selenocysteine increases expression ISO RGD:734299 6480464 selenomethylselenocysteine metabolite results in increased expression of BCL2L11 mRNA CTD PMID:25321483 Se-methylselenocysteine increases expression ISO RGD:734299 6480464 selenomethylselenocysteine metabolite results in increased expression of BCL2L11 mRNA CTD PMID:25321483 selenium atom multiple interactions ISO RGD:734299 6480464 BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium] more ... CTD PMID:17339365 selenium atom increases expression ISO RGD:734299 6480464 Selenium results in increased expression of BCL2L11 protein CTD PMID:17339365 selumetinib increases expression ISO RGD:734299 6480464 AZD 6244 results in increased expression of BCL2L11 protein CTD PMID:22729845 serpentine asbestos multiple interactions ISO RGD:734300 6480464 PRKD1 protein affects the reaction [Asbestos, Serpentine results in decreased expression of BCL2L11 protein], U 0126 promotes the reaction [Asbestos, Serpentine results in decreased expression of BCL2L11 protein] CTD PMID:19116364 serpentine asbestos decreases expression ISO RGD:734300 6480464 Asbestos, Serpentine results in decreased expression of BCL2L11 protein CTD PMID:19116364 silicon dioxide decreases expression ISO RGD:734299 6480464 Silicon Dioxide analog results in decreased expression of BCL2L11 mRNA, Silicon Dioxide results in decreased expression of BCL2L11 mRNA CTD PMID:25351596 , PMID:25895662 silicon dioxide increases expression ISO RGD:734300 6480464 Silicon Dioxide results in increased expression of BCL2L11 mRNA CTD PMID:19073995 sirolimus multiple interactions ISO RGD:734299 6480464 [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein more ... CTD PMID:21092744 , PMID:29054700 sirolimus decreases expression ISO RGD:734300 6480464 Sirolimus results in decreased expression of BCL2L11 protein CTD PMID:18097008 sirolimus increases expression ISO RGD:734299 6480464 Sirolimus results in increased expression of BCL2L11 protein CTD PMID:21092744 sodium arsenite increases expression ISO RGD:734300 6480464 sodium arsenite results in increased expression of BCL2L11 mRNA CTD PMID:16166651 sodium arsenite increases response to substance EXP 6480464 BCL2L11 protein results in increased susceptibility to sodium arsenite CTD PMID:16818494 sodium arsenite increases phosphorylation EXP 6480464 sodium arsenite results in increased phosphorylation of BCL2L11 protein CTD PMID:16818494 sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of BCL2L11 protein alternative form CTD PMID:20830294 sodium arsenite decreases expression ISO RGD:734300 6480464 sodium arsenite results in decreased expression of BCL2L11 mRNA CTD PMID:19822182 sodium arsenite multiple interactions EXP 6480464 SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of BCL2L11 protein] more ... CTD PMID:16818494 , PMID:20830294 sodium arsenite multiple interactions ISO RGD:734300 6480464 CEP-11004 inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] more ... CTD PMID:16166651 sodium chloride multiple interactions EXP 6480464 [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein, S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] CTD PMID:16030430 sorafenib affects localization ISO RGD:734299 6480464 sorafenib affects the localization of BCL2L11 protein CTD PMID:18200035 sorafenib increases expression ISO RGD:734299 6480464 sorafenib results in increased expression of BCL2L11 protein CTD PMID:18200035 sorafenib decreases expression ISO RGD:734299 6480464 sorafenib results in decreased expression of BCL2L11 protein CTD PMID:16109713 sorafenib multiple interactions ISO RGD:734299 6480464 [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3, 2-d)pyrimidine] results in increased expression of BCL2L11 protein CTD PMID:23036488 succimer multiple interactions ISO RGD:734300 6480464 [Succimer binds to Magnetite Nanoparticles] which results in increased expression of BCL2L11 mRNA, [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of BCL2L11 mRNA CTD PMID:21641980 , PMID:26378955 succimer multiple interactions ISO RGD:734299 6480464 [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2L11 mRNA CTD PMID:26378955 tamoxifen multiple interactions ISO RGD:734299 6480464 Tamoxifen promotes the reaction [methylselenic acid results in increased cleavage of BCL2L11 protein] CTD PMID:18790785 taurine multiple interactions EXP 6480464 Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein alternative form] CTD PMID:20830294 temozolomide increases expression ISO RGD:734299 6480464 temozolomide results in increased expression of BCL2L11 mRNA, temozolomide results in increased expression of BCL2L11 protein CTD PMID:26418950 temozolomide multiple interactions ISO RGD:734299 6480464 BCL2L11 mutant form inhibits the reaction [temozolomide results in increased cleavage of CASP9 protein], pyrazolanthrone inhibits the reaction [temozolomide results in increased expression of BCL2L11 mRNA] CTD PMID:26418950 testosterone increases expression EXP 6480464 Testosterone deficiency results in increased expression of BCL2L11 protein CTD PMID:20850791 tetrachloromethane increases expression ISO RGD:734300 6480464 Carbon Tetrachloride results in increased expression of BCL2L11 mRNA, Carbon Tetrachloride results in increased expression of BCL2L11 protein CTD PMID:17482686 tetrachloromethane multiple interactions ISO RGD:734300 6480464 PLG protein affects the reaction [Carbon Tetrachloride results in increased expression of BCL2L11 protein] CTD PMID:17482686 tetrathiomolybdate(2-) multiple interactions EXP 6480464 [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein, [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein CTD PMID:22276220 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of BCL2L11 mRNA CTD PMID:23411599 trametinib multiple interactions ISO RGD:734299 6480464 [trametinib co-treated with 2, 4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide] results in increased expression of BCL2L11 protein CTD PMID:22733540 trametinib increases expression ISO RGD:734299 6480464 trametinib results in increased expression of BCL2L11 protein CTD PMID:22733540 Tributyltin oxide increases expression ISO RGD:734300 6480464 bis(tri-n-butyltin)oxide results in increased expression of BCL2L11 mRNA CTD PMID:22434021 trichostatin A multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:14575637 , PMID:27188386 trichostatin A decreases expression ISO RGD:734299 6480464 trichostatin A results in decreased expression of BCL2L11 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A increases expression ISO RGD:734299 6480464 trichostatin A results in increased expression of BCL2L11 mRNA CTD PMID:24935251 trimellitic anhydride increases expression ISO RGD:734300 6480464 trimellitic anhydride results in increased expression of BCL2L11 mRNA CTD PMID:19042947 troglitazone decreases expression ISO RGD:734300 6480464 troglitazone results in decreased expression of BCL2L11 mRNA CTD PMID:28973697 urethane increases expression ISO RGD:734299 6480464 Urethane results in increased expression of BCL2L11 mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:734300 6480464 Valproic Acid affects the expression of BCL2L11 mRNA CTD PMID:17963808 valproic acid multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:734299 6480464 Valproic Acid results in decreased expression of BCL2L11 mRNA CTD PMID:23179753 more ... vemurafenib multiple interactions ISO RGD:734299 6480464 [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein, [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein] CTD PMID:27689874 vorinostat multiple interactions ISO RGD:734299 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:19509267 , PMID:27188386 vorinostat increases expression EXP 6480464 Vorinostat results in increased expression of BCL2L11 mRNA, Vorinostat results in increased expression of BCL2L11 protein CTD PMID:17331788 vorinostat increases expression ISO RGD:734299 6480464 vorinostat results in increased expression of BCL2L11 mRNA more ... CTD PMID:16144943 more ... withaferin A decreases expression ISO RGD:734299 6480464 withaferin A results in decreased expression of BCL2L11 protein CTD PMID:20438634 zinc atom increases expression ISO RGD:734299 6480464 Zinc results in increased expression of BCL2L11 mRNA CTD PMID:19071009 zinc protoporphyrin increases expression ISO RGD:734299 6480464 zinc protoporphyrin results in increased expression of BCL2L11 protein CTD PMID:27829220 zinc(0) increases expression ISO RGD:734299 6480464 Zinc results in increased expression of BCL2L11 mRNA CTD PMID:19071009 zoledronic acid multiple interactions ISO RGD:734299 6480464 [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA CTD PMID:16996129
Gene-Chemical Interaction Annotations
